시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 인간 메타뉴모바이러스(hMPV) 치료제 시장 보고서(2025년)
Human Metapneumovirus (hMPV) Therapeutics Global Market Report 2025
상품코드 : 1751019
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

인간 메타뉴모바이러스(hMPV) 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 예측 기간 동안 예상되는 성장은 지원 치료에 대한 수요 증가, 정부 및 비정부기구(NGO) 자금 증가, 호흡기 감염에 대한 인식 증가, 소아 호흡기 질환 환자 증가, 표적 치료에 대한 수요 증가 등에 기인한다고 생각됩니다. 이 기간의 주요 동향으로는 진단 플랫폼에의 기술 통합, 항바이러스제 개발의 진전, 백신 연구와 딜리버리 시스템의 진보, 기술 주도의 포인트 오브 케어 검사, 분자진단의 개선 등을 들 수 있습니다.

호흡기 감염의 유병률 증가는 향후 인간 메타뉴모바이러스(hMPV) 치료제 시장의 확대를 크게 이끌 것으로 예측됩니다. 감염 사례의 증가는 주로 대기 오염 수준의 증가에 기인합니다. hMPV 치료제는 항바이러스 치료나 지지 요법을 통해 바이러스의 복제나 염증을 억제하는 것으로, hMPV에 의한 호흡기 감염증의 치료에 중요한 역할을 완수하고 있습니다. 취약한 집단의 건강 상태가 개선됩니다. 2024년 6월, 정부 기관인 호주 보건복지연구원은 만성 폐쇄성 폐질환(COPD)이 2023년 호주 전체 질병 부담의 3.6%를 차지했다고 보고했습니다. COPD는 전체 호흡기 질환 부담의 50%를 차지하며, 2022년에는 약 63만 8,000명(전체 인구의 2.5%)이 COPD를 앓고 있는 것으로 추정했습니다. 따라서 호흡기 감염의 유병률 증가가 인간 메타뉴모바이러스(hMPV) 치료제 시장의 성장을 가속하고 있습니다.

인간 메타뉴모바이러스(hMPV) 치료제 시장의 주요 기업은 hMPV 감염을 효과적으로 치료하기 위해 단일클론항체와 같은 표적 항바이러스 요법의 개발에 주력하고 있습니다. 단일 클론 항체(mAbs)는 면역 체계가 질병과 싸우는 자연스러운 능력을 복제하는 실험실에서 생성된 단백질입니다. 이 항체는 유해한 항원이나 세포에 특이적으로 결합하여 중화함으로써 암이나 자가면역질환 등 다양한 질환에 대한 표적요법을 제공합니다. 2024년 10월, 영국에 본사를 둔 바이오 제약 회사인 Vicebio Ltd.는 골드만삭스 얼터너티브 및 기타 투자자들의 지원을 받아 TCGX가 주도하는 시리즈 B 파이낸싱으로 1억 달러를 확보했습니다. 2025년 중반까지 예비적인 결과가 나올 전망입니다. 또한 이번 자금 조달에 의해 RSV, hMPV, 파라인플루엔자 바이러스 3를 표적으로 하는 3가 백신인 VXB-251의 개발이 가속되어, 고령자 집단에 있어서 중대한 의료 과제의 해결을 목표로 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Human metapneumovirus (hMPV) therapeutics refers to medical treatments aimed at managing and alleviating the symptoms caused by hMPV, a respiratory virus that typically affects infants, older adults, and immunocompromised individuals. These therapeutics work by inhibiting viral replication, blocking the virus from entering host cells, and modulating the immune response to reduce inflammation and the severity of the disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug classes for hMPV therapeutics include antipyretics, decongestants, cough suppressants, and other related medications. An antipyretic is a substance that helps reduce fever by lowering the body's temperature, acting on the hypothalamus. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They are utilized in various end-use settings such as hospitals, clinics, diagnostic and reference laboratories, academic and research institutions, and other healthcare facilities.

The human metapneumovirus (hMPV) therapeutics market research report is one of a series of new reports from The Business Research Company that provides human metapneumovirus (hMPV) therapeutics market statistics, including the human metapneumovirus (hMPV) therapeutics industry global market size, regional shares, competitors with the human metapneumovirus (hMPV) therapeutics market share, detailed human metapneumovirus (hMPV) therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the human metapneumovirus (hMPV) therapeutics industry. This human metapneumovirus (hMPV) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human metapneumovirus (hMPV) therapeutics market size has grown strongly in recent years. It will grow from $0.66 billion in 2024 to $0.70 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historic period can be attributed to increased awareness of viral respiratory infections, a rising incidence of pediatric respiratory illnesses, higher hospitalization rates, expanded global health surveillance efforts, and a growing research focus on emerging respiratory viruses.

The human metapneumovirus (hMPV) therapeutics market size is expected to see strong growth in the next few years. It will grow to $0.90 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth projected during the forecast period can be attributed to the rising demand for supportive care treatments, increased government and NGO funding, growing awareness of respiratory infections, a rise in pediatric respiratory illness cases, and a higher demand for targeted therapies. Key trends during this period include the integration of technology in diagnostic platforms, advancements in antiviral drug development, progress in vaccine research and delivery systems, technology-driven point-of-care testing, and improvements in molecular diagnostics.

The growing prevalence of respiratory infections is expected to significantly drive the expansion of the human metapneumovirus (hMPV) therapeutics market in the future. Respiratory infections affect the respiratory tract, which includes the nose, throat, airways, and lungs. The increasing number of these infections is largely attributed to rising levels of air pollution. Pollutants such as particulate matter and nitrogen dioxide can irritate and weaken the respiratory tract, making individuals more vulnerable to infections. hMPV therapeutics play a crucial role in treating respiratory infections caused by hMPV by reducing viral replication and inflammation through antiviral treatments and supportive care. This improves health outcomes, especially for vulnerable groups such as infants, the elderly, and immunocompromised patients. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that Chronic Obstructive Pulmonary Disease (COPD) contributed to 3.6% of Australia's total disease burden in 2023. COPD accounted for 50% of the overall respiratory disease burden, with an estimated 638,000 people (2.5% of the population) living with COPD in 2022. Therefore, the increasing prevalence of respiratory infections is driving growth in the human metapneumovirus (hMPV) therapeutics market.

Leading companies in the human metapneumovirus (hMPV) therapeutics market are focusing on developing targeted antiviral therapies, such as monoclonal antibodies, to effectively treat hMPV infections. Monoclonal antibodies (mAbs) are laboratory-produced proteins that replicate the immune system's natural ability to fight diseases. These antibodies offer targeted therapy for a range of conditions, including cancer and autoimmune disorders, by specifically binding to and neutralizing harmful antigens or cells. For instance, in October 2024, Vicebio Ltd., a UK-based biopharmaceutical company, secured $100 million in Series B financing, led by TCGX with support from Goldman Sachs Alternatives and other investors. This funding will advance the Phase 1 clinical trial of VXB-241, a bivalent vaccine targeting RSV and hMPV, with preliminary results expected by mid-2025. The funding will also accelerate the development of VXB-251, a trivalent vaccine targeting RSV, hMPV, and Parainfluenza Virus 3, aiming to address significant medical challenges in older populations.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical giant, acquired Icosavax, Inc. for $1.1 billion. This acquisition allows AstraZeneca to strengthen its vaccine and respiratory infection portfolio by incorporating Icosavax's innovative virus-like particle (VLP) technology and its potential first-in-class combination vaccine for RSV and hMPV. Icosavax, Inc., a U.S.-based biopharmaceutical company, is developing virus-like particle vaccines, including a promising first-in-class combination vaccine targeting both RSV and hMPV.

Major players in the human metapneumovirus (hmpv) therapeutics market are Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Riverside Health System, Narayana Health, Vir Biotechnology Inc., Fortis Healthcare, Apollo Diagnostics, Pathkind Diagnostics Pvt Ltd, Max Healthcare, LalPathLabs, Bio Farma, Metropolis Healthcare, American Lung Association, Enanta Pharmaceuticals Inc., Regency Healthcare, The Native Antigen Company, Max Lab, Agilus Diagnostics.

North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human metapneumovirus (hMPV) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human metapneumovirus (hMPV) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human metapneumovirus (hMPV) therapeutics market consists of revenues earned by entities providing services such as antiviral drug development, vaccine research, diagnostic testing, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus (hMPV) therapeutics market also includes sales of antiviral medications, immunotherapies, vaccines, and related diagnostic kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Metapneumovirus (hMPV) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human metapneumovirus (hmpv) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for human metapneumovirus (hmpv) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human metapneumovirus (hmpv) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Human Metapneumovirus (hMPV) Therapeutics Market Characteristics

3. Human Metapneumovirus (hMPV) Therapeutics Market Trends And Strategies

4. Human Metapneumovirus (hMPV) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Metapneumovirus (hMPV) Therapeutics Growth Analysis And Strategic Analysis Framework

6. Human Metapneumovirus (hMPV) Therapeutics Market Segmentation

7. Human Metapneumovirus (hMPV) Therapeutics Market Regional And Country Analysis

8. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market

9. China Human Metapneumovirus (hMPV) Therapeutics Market

10. India Human Metapneumovirus (hMPV) Therapeutics Market

11. Japan Human Metapneumovirus (hMPV) Therapeutics Market

12. Australia Human Metapneumovirus (hMPV) Therapeutics Market

13. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market

14. South Korea Human Metapneumovirus (hMPV) Therapeutics Market

15. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market

16. UK Human Metapneumovirus (hMPV) Therapeutics Market

17. Germany Human Metapneumovirus (hMPV) Therapeutics Market

18. France Human Metapneumovirus (hMPV) Therapeutics Market

19. Italy Human Metapneumovirus (hMPV) Therapeutics Market

20. Spain Human Metapneumovirus (hMPV) Therapeutics Market

21. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market

22. Russia Human Metapneumovirus (hMPV) Therapeutics Market

23. North America Human Metapneumovirus (hMPV) Therapeutics Market

24. USA Human Metapneumovirus (hMPV) Therapeutics Market

25. Canada Human Metapneumovirus (hMPV) Therapeutics Market

26. South America Human Metapneumovirus (hMPV) Therapeutics Market

27. Brazil Human Metapneumovirus (hMPV) Therapeutics Market

28. Middle East Human Metapneumovirus (hMPV) Therapeutics Market

29. Africa Human Metapneumovirus (hMPV) Therapeutics Market

30. Human Metapneumovirus (hMPV) Therapeutics Market Competitive Landscape And Company Profiles

31. Human Metapneumovirus (hMPV) Therapeutics Market Other Major And Innovative Companies

32. Global Human Metapneumovirus (hMPV) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Metapneumovirus (hMPV) Therapeutics Market

34. Recent Developments In The Human Metapneumovirus (hMPV) Therapeutics Market

35. Human Metapneumovirus (hMPV) Therapeutics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기